This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Focus on Women's Mental Health

Estrogen Augmentation of Antidepressants in Perimenopausal Depression: A Pilot Study

Melinda L. Morgan, PhD; Ian A. Cook, MD; Andrea J. Rapkin, MD; and Andrew F. Leuchter, MD

Published: June 15, 2005

Article Abstract

Objective: To investigate the effects ofestrogen augmentation on mood and memory inwomen with perimenopausal depression who hadexperienced a partial response to antidepressantmedications.

Method: In a double-blind, placebo-controlledtrial, 17 subjects taking antidepressant medicationwere randomly assigned to either 0.625 mg/day ofconjugated estrogen (N = 11) or matching placebo(N = 6) for 6 weeks. Women between the ages of40 and 60 years with DSM-IV major depressivedisorder (MDD) in partial remission who hadbeen taking antidepressant medication for a minimumof 8 weeks and were experiencing 1 or moreperimenopausal symptoms (hot flashes, nightsweats, irregular periods, sleep disturbance,memory impairment) were recruited from thecommunity. The primary outcome measures werethe final scores for the Hamilton Rating Scale forDepression (HAM-D) and the Buschke SelectiveReminding Test. Data were gathered from April2002 to August 2003.

Results: Women receiving estrogen had asignificantly larger decrease in HAM-D scoresthan women receiving placebo (t = 2.86, df = 15,p = .012). Group differences in tests of verbalmemory were not significant, although improvedscores in verbal memory were significantly correlatedwith a decrease in follicle-stimulating hormone(p = .021).

Conclusion: Short-term, low-dose estrogenaugmentation of antidepressant medication wassignificantly associated with improved mood,but not memory, in perimenopausal womenwith MDD in partial remission.

Volume: 66

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...